{"id":6570,"date":"2023-04-04T10:22:26","date_gmt":"2023-04-04T10:22:26","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=6570"},"modified":"2023-04-04T10:22:26","modified_gmt":"2023-04-04T10:22:26","slug":"europe-com-publication-of-the-regulation-amending-clp","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/","title":{"rendered":"EUROPE \u2013 COM : Publication of the regulation amending CLP"},"content":{"rendered":"<p style=\"text-align: justify\"><span style=\"font-weight: 400\">Following the <\/span><a href=\"https:\/\/environment.ec.europa.eu\/publications\/proposal-clp-revision_en\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">proposed revision of the CLP Regulation<\/span><\/a><span style=\"font-weight: 400\"> and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous chemicals (<\/span><a href=\"https:\/\/lynxee.consulting\/en\/europe-com-proposal-for-the-revision-of-the-clp-regulation\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">see our previous article<\/span><\/a><span style=\"font-weight: 400\">), the Commission published on 31 March 2023 in the Official Journal of the European Union a <\/span><a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32023R0707&amp;qid=1680506244011\" target=\"_blank\" rel=\"noopener\"><b>Delegated Regulation (EU) 2023\/707<\/b><\/a><span style=\"font-weight: 400\"> amending Regulation (EC) No 1272\/2008 as regards hazard classes and criteria for the classification, labelling and packaging of substances and mixtures.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">Regulation 2023\/707 therefore adapted the Annexes to \u00a0<a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/FR\/TXT\/?uri=celex%3A32008R1272\" target=\"_blank\" rel=\"noopener\">Regulation (EC) No 1272\/2008<\/a> as follows :<\/span><\/p>\n<ul style=\"text-align: justify\">\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Annex I :<\/span><b> Addition of classification criteria for substances<\/b><span style=\"font-weight: 400\"> identified as <\/span><b>endocrine disrupters for human health or the environment<\/b><span style=\"font-weight: 400\">, <\/span><b>PBT (persistent, bioaccumulative, toxic)<\/b><span style=\"font-weight: 400\"> or <\/span><b>vPvB (very persistent, very bioaccumulative)<\/b><span style=\"font-weight: 400\">, <\/span><b>PMT (persistent, mobile, toxic)<\/b><span style=\"font-weight: 400\"> or <\/span><b>vPvM (very persistent, very mobile)<\/b><span style=\"font-weight: 400\">, as well as <\/span><b>thresholds for the classification of mixtures<\/b><span style=\"font-weight: 400\"> and indicators (signal words, hazard statements, precautionary statements) related to the<\/span><b> hazard communication<\/b><span style=\"font-weight: 400\">. As the level of evidence as regards endocrine disrupting properties may be of different scientific strength,<\/span><b> two categories of endocrine disruptors have been created<\/b><span style=\"font-weight: 400\">: <\/span><b>known or presumed endocrine disruptors (category 1)<\/b><span style=\"font-weight: 400\"> and <\/span><b>suspected endocrine disruptors (category 2)<\/b><span style=\"font-weight: 400\">, both for human health and for the environment.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">In order to give suppliers of substances and mixtures time to adapt to these<\/span><b> new classification and labelling provisions<\/b><span style=\"font-weight: 400\">, they are<\/span><b> applicable :<\/b><\/p>\n<ul>\n<li style=\"list-style-type: none\">\n<ul style=\"text-align: justify\">\n<li><b>from 1 May 2025 at the latest for substances,<\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none\">\n<ul style=\"text-align: justify\">\n<li><b>from 1 May 2026 at the latest for mixtures.<\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">However, substances (respectively mixtures) which were placed on the market before 1 May 2025 (respectively 1 May 2026), are not required to be classified and labelled according to these new criteria until 1 November 2026 (respectively 1 May 2028).<\/span><\/p>\n<ul style=\"text-align: justify\">\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Annex II : Addition of a new criterion triggering the hazard statement EUH210 &#8211; &#8220;Safety Data Sheet available on request&#8221; on the label, for mixtures not classified as hazardous but containing a substance classified as a category 2 endocrine disruptor for human health or the environment, at a content equal to or higher than 0.1%.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Annex III : <\/span><b>Addition of the following new hazard statements <\/b><span style=\"font-weight: 400\">:<\/span>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH380 &#8211; &#8220;May cause endocrine disruption in humans&#8221;,\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH381 &#8211; &#8220;Suspected of causing endocrine disruption in humans&#8221;,\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH430 &#8211; &#8220;May cause endocrine disruption in the environment&#8221;,<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH431\u00a0 &#8211; &#8220;Suspected of causing endocrine disruption in the environment&#8221;,\u00a0\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH440 &#8211; &#8220;Accumulates in the environment and living organisms including in humans&#8221;,\u00a0\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH441 &#8211; &#8220;Strongly accumulates in the environment and living organisms including in humans&#8221;,\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH450 &#8211; &#8220;Can cause long-lasting and diffuse contamination of water resources&#8221; and<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">EUH451 &#8211; &#8220;Can cause very long-lasting and diffuse contamination of water resources&#8221;.\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Annex VI : <\/span><b>Addition of the following new hazard classes and categories\u2019 codes <\/b><span style=\"font-weight: 400\">:<\/span>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Endocrine disruptor for human health : ED HH 1 or ED HH 2,<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Endocrine disruptor for the environment :ED ENV 1 or ED ENV 2,<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Persistent, bioaccumulative and toxic : PBT,<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Very persistent and very bioaccumulative : vPvB,<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Persistent, mobile and toxic : PMT and<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Very persistent and very mobile : vPvM.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">In case <\/span><b>new pictograms<\/b><span style=\"font-weight: 400\"> are created for these new hazard classes, they should be agreed at UNGHS first so that they can apply across the UNGHS members.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">The Regulation comes into force from<\/span><b> 20 April 2023<\/b><span style=\"font-weight: 400\">.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\"><b>To download:\u00a0<\/b><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32023R0707&amp;qid=1680506244011\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">COMMISSION DELEGATED REGULATION (EU) 2023\/707 of 19 December 2022 amending Regulation (EC) No 1272\/2008 as regards hazard classes and criteria for the classification, labelling and packaging of substances and mixtures<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\">\n<p style=\"text-align: justify\"><b>See also our previous articles:\u00a0<\/b><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/lynxee.consulting\/en\/europe-com-proposal-for-the-revision-of-the-clp-regulation\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">EUROPE \u2013 COM : Proposal for the revision of the CLP Regulation<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\">\n<p style=\"text-align: justify\">\n<p style=\"text-align: justify\"><b>Lynxee consulting<\/b><span style=\"font-weight: 400\">\u2019s team is at your disposal to answer your questions.<\/span><\/p>\n<p style=\"text-align: justify\"><b>Contact us!<\/b> <a href=\"http:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">http:\/\/lynxee.consulting\/en\/contact\/<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\">\n<h6 style=\"text-align: justify\">\n<span style=\"font-weight: 400\">Photo credit:<\/span> <span style=\"font-weight: 400\">\u00a0<\/span><span style=\"font-weight: 400\">geralt<\/span><span style=\"font-weight: 400\">\/pixabay<\/span><\/h6>\n","protected":false},"excerpt":{"rendered":"<p>Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous chemicals (see our previous<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":11,"featured_media":6562,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[67,404,435,419,420,436,437],"class_list":["post-6570","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-clp-en","tag-commission-en","tag-endocrine-disruptor","tag-pbt-en","tag-pmt-en","tag-vpvb-en","tag-vpvm-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUROPE \u2013 COM : Publication of the regulation amending CLP - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUROPE \u2013 COM : Publication of the regulation amending CLP - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T10:22:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/04\/office-g21a0b3e87_1920_geralt.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tanalou Djae\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tanalou Djae\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/\"},\"author\":{\"name\":\"Tanalou Djae\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/da8f9efd807b456019d890b71820bbd4\"},\"headline\":\"EUROPE \u2013 COM : Publication of the regulation amending CLP\",\"datePublished\":\"2023-04-04T10:22:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/\"},\"wordCount\":560,\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/office-g21a0b3e87_1920_geralt.jpg\",\"keywords\":[\"CLP\",\"commission\",\"endocrine disruptor\",\"PBT\",\"PMT\",\"vPvB\",\"vPvM\"],\"articleSection\":[\"Regulation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/\",\"name\":\"EUROPE \u2013 COM : Publication of the regulation amending CLP - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/office-g21a0b3e87_1920_geralt.jpg\",\"datePublished\":\"2023-04-04T10:22:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/da8f9efd807b456019d890b71820bbd4\"},\"description\":\"Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/office-g21a0b3e87_1920_geralt.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/office-g21a0b3e87_1920_geralt.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-com-publication-of-the-regulation-amending-clp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUROPE \u2013 COM : Publication of the regulation amending CLP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lynxee.consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/da8f9efd807b456019d890b71820bbd4\",\"name\":\"Tanalou Djae\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg\",\"caption\":\"Tanalou Djae\"},\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/author\\\/tanalou-djae\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUROPE \u2013 COM : Publication of the regulation amending CLP - Lynxee consulting","description":"Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/","og_locale":"en_US","og_type":"article","og_title":"EUROPE \u2013 COM : Publication of the regulation amending CLP - Lynxee consulting","og_description":"Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous","og_url":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/","og_site_name":"Lynxee consulting","article_published_time":"2023-04-04T10:22:26+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/04\/office-g21a0b3e87_1920_geralt.jpg","type":"image\/jpeg"}],"author":"Tanalou Djae","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tanalou Djae","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#article","isPartOf":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/"},"author":{"name":"Tanalou Djae","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/da8f9efd807b456019d890b71820bbd4"},"headline":"EUROPE \u2013 COM : Publication of the regulation amending CLP","datePublished":"2023-04-04T10:22:26+00:00","mainEntityOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/"},"wordCount":560,"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/04\/office-g21a0b3e87_1920_geralt.jpg","keywords":["CLP","commission","endocrine disruptor","PBT","PMT","vPvB","vPvM"],"articleSection":["Regulation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/","url":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/","name":"EUROPE \u2013 COM : Publication of the regulation amending CLP - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/04\/office-g21a0b3e87_1920_geralt.jpg","datePublished":"2023-04-04T10:22:26+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/da8f9efd807b456019d890b71820bbd4"},"description":"Following the proposed revision of the CLP Regulation and the introduction of new hazard classes for endocrine disruptors (EDs) and other hazardous","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/04\/office-g21a0b3e87_1920_geralt.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2023\/04\/office-g21a0b3e87_1920_geralt.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/europe-com-publication-of-the-regulation-amending-clp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"EUROPE \u2013 COM : Publication of the regulation amending CLP"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/da8f9efd807b456019d890b71820bbd4","name":"Tanalou Djae","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2021\/10\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2021\/10\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2021\/10\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg","caption":"Tanalou Djae"},"url":"https:\/\/lynxee.consulting\/en\/author\/tanalou-djae\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/6570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=6570"}],"version-history":[{"count":2,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/6570\/revisions"}],"predecessor-version":[{"id":6572,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/6570\/revisions\/6572"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/6562"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=6570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=6570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=6570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}